Winrevair is used to treat adults with pulmonary arterial hypertension (PAH). It helps improve exercise ability, daily functioning, and lowers the risk of the condition getting worse.
To Get Full Access :
To Get Full Access :
Winrevair is used to treat adults with pulmonary arterial hypertension (PAH). It helps improve exercise ability, daily functioning, and lowers the risk of the condition getting worse.
The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.
Molecule Name :
Innovator :
Approval Date :
Data Exclusivity Expiry :
Market Exclusivity Expiry :
Dosage Form :
Strength :
Therapeutic Category :
Revenue ($M) :
2025 :
2026 :
2027 :
2028 :
2029 :
2030 :
2031 :





For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.